Estimate, GmbH   Report issue

For profit Phase 2
Founded: Hachenburg Germany (1992)
Status: No NME R&D (1992)

Organization Overview

First Clinical Trial
2008
NCT00775073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

bevacizumab (avastin) (1 trial)

deferasirox (exjade) (1 trial)

everolimus (zortress) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Fatty Liver (Phase 2)

Liver Neoplasms (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3